Cannara Biotech Inc (V:LOVE) — Market Cap & Net Worth
Market Cap & Net Worth: Cannara Biotech Inc (LOVE)
Cannara Biotech Inc (V:LOVE) has a market capitalization of $126.80 Million (CA$175.28 Million) as of August 1, 2026. Listed on the V stock exchange, this Canada-based company holds position #18232 globally and #603 in its home market, demonstrating a 3.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cannara Biotech Inc's stock price CA$1.83 by its total outstanding shares 95782148 (95.78 Million). See how much does Cannara Biotech Inc reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Cannara Biotech Inc Market Cap History: 2019 to 2026
Cannara Biotech Inc's market capitalization history from 2019 to 2026. Data shows change from $86.61 Million to $126.80 Million (-6.85% CAGR).
Cannara Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cannara Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.12x
Cannara Biotech Inc's market cap is 1.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.22x
Cannara Biotech Inc's market cap is 9.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $86.61 Million | $2.10 Million | -$12.32 Million | 41.30x | N/A |
| 2020 | $55.43 Million | $2.47 Million | -$12.48 Million | 22.40x | N/A |
| 2021 | $93.54 Million | $16.29 Million | -$1.53 Million | 5.74x | N/A |
| 2022 | $65.82 Million | $35.84 Million | $2.31 Million | 1.84x | 28.55x |
| 2023 | $57.51 Million | $57.26 Million | $6.95 Million | 1.00x | 8.28x |
| 2024 | $51.27 Million | $81.75 Million | $6.44 Million | 0.63x | 7.96x |
| 2025 | $120.56 Million | $107.20 Million | $13.08 Million | 1.12x | 9.22x |
Competitor Companies of LOVE by Market Capitalization
Companies near Cannara Biotech Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Cannara Biotech Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Cannara Biotech Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Cannara Biotech Inc's market cap moved from $86.61 Million to $ 126.80 Million, with a yearly change of -6.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$126.80 Million | +5.17% |
| 2025 | CA$120.56 Million | +135.14% |
| 2024 | CA$51.27 Million | -10.84% |
| 2023 | CA$57.51 Million | -12.63% |
| 2022 | CA$65.82 Million | -29.63% |
| 2021 | CA$93.54 Million | +68.75% |
| 2020 | CA$55.43 Million | -36.00% |
| 2019 | CA$86.61 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Cannara Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $126.80 Million USD |
| MoneyControl | $126.80 Million USD |
| MarketWatch | $126.80 Million USD |
| marketcap.company | $126.80 Million USD |
| Reuters | $126.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cannara Biotech Inc
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. I… Read more